The randomized phase 3 trials proved that second or later-line anti-PD-1/PD-L1 monotherapy does not prolong median progression-free survival compared with chemotherapy in RM-NPC patients from Keynote 122 and Even’ s study16,17,43. The gene discussed is CD274; the disease is nasopharyngeal carcinoma.